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3-Iodothyronamine (T1AM) is the last iodinated thyronamine generated from thyroid 
hormone alternative metabolism found circulating in rodents and in humans. So far, the 
physiopathological meaning of T1AM tissue levels is unknown. Much is instead known 
on T1AM pharmacological effects in rodents. Such evidence indicates that T1AM acutely 
modifies, with high potency and effectiveness, rodents’ metabolism and behavior, often 
showing inverted U-shaped dose–response curves. Although several possible targets 
for T1AM were identified, the mechanism underlying T1AM behavioral effects remains 
still elusive. T1AM pharmacokinetic features clearly indicate the central nervous system 
is not a preferential site for T1AM distribution but it is a site where T1AM levels are 
critically regulated, as it occurs for neuromodulators or neurotransmitters. We here 
summarize and discuss evidence supporting the hypothesis that central effects of T1AM 
derive from activation of intracellular and possibly extracellular pathways. In this respect, 
consisting evidence indicates the intracellular pathway is mediated by the product of 
T1AM phase-I non-microsomal oxidation, the 3-iodothryoacetic acid, while other data 
indicate a role for the trace amine-associated receptor, isoform 1, as membrane target 
of T1AM (extracellular pathway). Overall, these evidence might sustain the non-linear 
dose–effect curves typically observed when increasing T1AM doses are administered 
and reveal an interesting and yet unexplored link between thyroid, monoamine oxidases 
activity and histamine.
Keywords: 3-iodothyronamine, 3-iodothyroacetic acid, histamine, trace amine-associated receptors, monoamine 
oxidases
BACKGROUnD
3-Iodothyronamine (T1AM) is the last iodinated thyronamine produced by thyroid hormone (TH) 
metabolism and supposed to mediate TH non-genomic effects. From its identification in rodent 
tissues (1), T1AM was included within the family of the trace amines (TAs) and identified as 
an endogenous ligand for trace amine-associated receptors (TAARs), a family of constitutively 
active G protein-coupled receptors with species and tissue-specific expression cross-talking with 
the dopaminergic and the serotoninergic transmission (2, 3). This latter feature raised the inter-
est around TAAR agonists, and then on T1AM, as potential treatments for controlling craving, 
pain, and neuropsychiatric illnesses. Consistently, the determination of endogenous T1AM brain 
levels or T1AM pharmacological administration would play diagnostic or therapeutic roles, 
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respectively, in clinical manifestations of diseases involving 
dopamine release. However, after more than 10  years from 
T1AM discovery, whether central effects described following 
pharmacological administration of T1AM can be ascribed 
to TAAR activation remains an open issue, and we have no 
indications of T1AM levels in psychiatric or in drug-abusing 
patients. An important contribution to this uncertainness 
derives from the lack of pharmacological antagonists of TAARs 
with favorable pharmacokinetic features for in vivo administra-
tion. Instead, based on the current knowledge, T1AM presents 
a puzzling pharmacological profile suggesting a role as a cell 
messenger, behaving as a hormone and/or a neuromodulator, a 
function likely mediated also by 3-iodothryoacetic acid (TA1), 
the product of T1AM non-microsomal phase-I metabolism. 
T1AM may also interact with high-affinity targets including 
G protein-coupled receptors as TAAR1, or ion channels (4–6). 
We here summarize and discuss evidence indicating that beha-
vioral effects of T1AM deserve to receive the attention of the 
investigators since, in the central nervous system, the phar ma-
cokinetic features of this amine include a novel role for mito-
chondrial monoamine oxidases (MAO).
T1AM PHARMACOKineTiC
Few notes on Tissue Distribution
Consisting evidence indicates that the tandem mass spectrom-
etry represents the most reliable method to determine T1AM 
tissue levels, whereas some difficulties remain for measuring 
T1AM plasma levels (7) because T1AM administered to rodents 
circulated almost completely bound reversibly and with high 
affinity to Apo-B100, the main protein fraction of LDL and VLDL 
lipoproteins (8). This evidence indicated that T1AM has a specific 
plasma protein carrier, a condition usually reserved to hormones 
and vitamins and controlling amine pharmacokinetic.
LDL and VLDL are physiologically implicated in regulat-
ing the homeostasis of triglycerides and cholesterol, including 
their intracellular transport, by activating respective receptors 
(VLD-R and LDL-R), which are expressed almost ubiquitously 
but concentrated in the liver. Apo-B100 is the determinant for 
the recognition of lipoprotein receptors, their endocytosis, and 
recycling from plasma membrane. According to Roy et  al. (8), 
the interaction of VLDL or LDL with their respective hepatic 
receptors represents a highly effective mechanism for the intra-
cellular transport of T1AM. Once inside cells, T1AM, as well as 
cholesterol and triglycerides, may activate their own intracellular 
targets. In particular, since triglycerides may activate PPAR alpha 
while oxysterols the liver X receptor, genomic effects of T1AM 
may also represent epiphenomena derived from the activation 
of these targets (9, 10). Chiellini et  al. (11) produced indica-
tions about T1AM distribution in mouse tissues. Following i.p. 
administration of [125I]-T1AM, the radioactivity recovered in 
tissues confirmed the liver and the gallbladder were preferential 
sites of T1AM distribution, reinforcing the link between T1AM, 
lipoproteins, and their receptor signaling, while the adipose 
tissue and skeletal muscle were described as sites where T1AM 
accumulated. Likewise, a small percentage of the radioactivity 
administered was recovered in the brain where such percentage 
could be even overestimated due to the accumulation of radioac-
tive metabolites of T1AM. If we consider that circulating T1AM 
is almost completely bound to ApoB-100, it becomes relevant to 
understand how this amine can cross the blood–brain barrier 
(BBB) and if this passage represents a limit for T1AM degradation 
(Figure 1).
The BBB consists of a specialized network of fenestrated 
capil laries in tight relation with astrocytes projecting to neurons, 
working as a physical barrier to the passage of humoral fac-
tors, including cholesterol and other lipids. Cholesterol flux is 
directed by lipoproteins but only the high-density lipoproteins 
can traverse the BBB. However, apolipoproteins, including Apo-
E, are present in brain areas and in the cerebrospinal fluid (12). 
In addition, since endothelial cells express Apo-B100 (13), it can 
be argued apolipoproteins can be synthetized in brain areas. In 
this respect, astrocytes, which also express high levels of VLDL-R 
and LDL-R (14), have been indicated as the most likely candidate 
cell for apolipoprotein synthesis. Overall, the presence of apoli-
poproteins and of their receptors suggests that apolipoproteins 
may have functions in the brain. Consistently, evidence indicated 
lipoproteins can stimulate the cognitive function in the hip-
pocampus and regulate energy balance in the hypothalamus (14).
3-Iodothyronamine is physiologically present in mouse thy-
roid, and it distributes in the gland following pharmacological 
administration. In the thyroid, the half-life of T1AM was the 
highest among the tissues analyzed (11).
Manni et al. (15) demonstrated that, following i.c.v. injection 
of T1AM, this amine was recovered in the systemic circulation, 
thus indicating it can pass but also exit the BBB. Interestingly, 
T1AM systemic bioavailability significantly increased when 
its oxidative metabolism was inhibited, i.e., mice pretreated 
with clorgyline, a mitochondrial MAO inhibitor. Consistently, 
Laurino et  al. (16) demonstrated T1AM disappearance from 
the medium of cultured organotypic hippocampal slices associ-
ated with the contemporaneous accumulation of TA1 and that 
that, in mouse brain, T1AM pharmacologically administered is 
metabolized to TA1.
T1AM Metabolism
For its chemical structure, T1AM has the requisites to be a 
substrate for amine oxidases including MAO (17), ubiquitous 
enzyme activities, and semicarbazide-sensitive amine oxidases 
(SSAOs), a heterogeneous class of enzymes localized on cell 
plasma membranes. Two isoforms of MAO have been cloned, 
i.e., MAO-A and MAO-B (18) with MAO-A mainly present in 
catecholaminergic and MAO-B in serotonergic and histaminer-
gic neurons and astrocytes (19, 20).
Both MAO and SSAO are included within the pattern of 
non-microsomal phase-I metabolizing enzymes. Due to the 
absence of SSAOs in the brain, T1AM oxidative metabolism at 
this site can be carried on only by MAO. Lehmphul et al. (17) 
first demonstrated T1AM is a substrate for MAO-B opening to 
a new function for MAO-B (21). Furthermore, the involvement 
of MAO catalysis in T1AM degradation implies physiopatho-
logical and pharmacological consequences. In fact, the extent of 
T1AM degradation would depend on MAO-B tissue expression 
levels and on pathological conditions altering MAO-B promoter 
FiGURe 1 | Distribution and metabolism of 3-iodothyronamine (T1AM) in the brain. T1AM is physiologically present in the brain of mice and its levels increse after 
pharmaoclogical administrtaion thus indicating T1AM can pass the blood brain barrier (BBB). The mechanism of T1AM passage through the BBB remains elusive 
yet. Three possible hypotheses are presented, including endocytosis of lipoprotein receptor, carrier-mediated transport, or transcytosis of free T1AM.  
One inside the brain, T1AM is manly metabolized to 3-iodothyroacetic acid (TA1) by the activity of mitochondrial monoamine oxidases (MAO).
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activity, including diabetes, inflammation, thyroid diseases, or 
aging. Secondarily, T1AM oxidation is expected to be modified 
by treatments including inhibitors of MAO-B as those used in the 
control of the early symptoms of Parkinson’s disease (18).
In addition, since MAO catalysis produces hydrogen peroxide, 
reactive aldehydes, and ammonia, the degradation of T1AM by 
MAO-B potentially alters the cell redox state (19). The impact 
of T1AM degradation on neuron redox state might represent a 
novel and interesting issue to explore.
Furthermore, the fact that in the thyroid a very high mitochon-
drial MAO-A, and low MAO-B, is present (22) might account for 
the long half-life of the amine in the gland.
The effects of T1AM Suggests the  
Amine Behaves as a Hormone or  
as a neuromodulator
Experimental data indicate T1AM is a potent and effective 
modifier of the behavior and of the metabolism of rodents. 
Such effects onset within 15–30 min from amine administra-
tion and often show inverted U-shaped dose–effect curves. 
This characteristic suggests increasing T1AM doses (i) rapidly 
induce desensitization of a target(s) or (ii) recruit different 
targets controlling opposite effects. Whatever the mechanism, 
the inverted dose–effect curve indicates it is possible to predict 
the dose of T1AM that needs to be administered to observe a 
desired effect (Figure  2) and stresses the importance to study 
T1AM at its lowest effective dose.
Furthermore, the acute central effects of T1AM are followed 
by long-term effects based on the activation of gene transcrip-
tion. Whether these effects are driven directly by T1AM, TA1, or 
indirectly by T1AM or TA1-induced release of neurotransmitters 
is unknown yet. Considering the current knowledge, histamine 
has been identified as one of the neurotransmitters involved in 
T1AM effects.
Histamine in the brain accumulates in mast cells, astrocytes 
(23), and in the few histaminergic neurons that are concentrated 
in the hypothalamus from which they project to most of the 
brain areas including the hippocampus and cortex (24). Neuronal 
histamine is implicated in memory, control of the sleep/wake 
cycle, feeding, thermoregulation, motility, and it is considered 
an endogenous neuroprotective mediator against excitotoxicity 
(25, 26). Histamine in the brain is mainly degraded by N-methyl 
transferase producing N-methylhistamine (27) which is, in turn, 
a good substrate for MAO-B. Consequently, histamine and T1AM 
may compete for MAO-B catalysis.
FiGURe 2 | Differences and similarities between T1AM and TA1 pharmacological effects. T1AM and TA1 share pharmacological effects that are described by 
inverted dose–effect curves. The cartoon indicates similarities and differences among central effects of equimolar doses of T1AM and TA1. Abbreviations: T1AM, 
3-iodothyronamine; TA1, 3-iodothyroacetic acid; T0AM, thyronamine; MAO, monoamine oxidases.
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Hypothalamic effects of 
Pharmacologically Administered T1AM
Scanlan et al. (1) first described that high T1AM doses (50 mg/kg) 
induced a deep reduction of mice body temperature. Later, 
Doyle et  al. (28) demonstrated T1AM rescued neurons from 
excitotoxicity by inducing hypothermia in an experimental 
model of cerebral ischemia. Some years later, James et  al. (29) 
clarified that the hypothermia was secondary to increased heat 
dispersion caused by tail vasodilation (29) and indicated T1AM 
as a hypothalamic regulator of the temperature set point of 
warm–sensitive neurons. This mechanism might also explain the 
potent reduction of pain threshold to hot stimuli described after 
T1AM administration in mice (15).
Dhillo et  al. (30) reported that T1AM reduced feeding of 
ad libitum-fed mice, and Ju et al. (31) described the amine shifted 
energy substrate utilization from glucose to lipids. Overall, this 
evidence contributed to delineate T1AM as a compound inducing 
a hypometabolic status. However, Manni et al. (15) unmasked the 
hyperphagic effect of the amine. In fact, the authors found that, at 
condition of fasting, i.c.v. injected low T1AM doses (1.3 µg/kg) 
still induced hypophagia and rapidly increased plasma glucose. 
Instead, injection of higher T1AM doses induced hyperphagia 
without raising plasma glycemia. Because of this, T1AM can be 
considered as a potent hypophagic compound able to counter-
act the fasting-induced tendency of mice to overfeeding. This 
effect is likely sustained by the increase of plasma glycemia. 
Consistently, at doses producing hyperphagia, plasma glycemia 
was not modified. In any case, the raise of plasma glycemia was a 
hypothalamic-mediated effect and it went in the opposite direc-
tion compared with the anti-hyperglycemic effect described for 
other TAs (32).
In addition, Manni et al. (15) demonstrated, for the first time, 
that T1AM oxidative metabolism was essential for T1AM hyper-
phagia. In fact, in mice pretreated with clorgyline, an inhibitor 
of MAO activity, hyperphagia disappeared while the hypophagic 
effect remained. Then, hypophagia could derived from the rec-
ognition of a high-affinity target (extracellular pathway), while 
hyperphagia depended on some products of T1AM oxidative 
deamination, including TA1 (intracellular pathway).
James et al. (29) reported that T1AM stimulated mice wake-
fulness when injected in the preoptic region, confirming the 
activity on hypothalamus. Furthermore, T1AM injected i.c.v. or 
systemically administered induced hyperalgesia to hot stimuli 
(33). The stimulation of peripheral sensory neurons translated in 
pERK1/2 of the interneurons of dorsal root ganglia (DRG), thus 
involving the spinothalamic pathway in the transmission of pain 
transmission (34).
T1AM Activity at Hippocampus
Among the main interesting effects elicited by T1AM is its acti-
vity on memory circuits possibly indicating some effectiveness of 
the amine in diseases characterized by memory impairments (35).
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3-Iodothyronamine given i.c.v. or systemically, increased 
pERK1/2 and pAKT levels in different brain areas, including 
the hippocampus and hypothalamus (33), it acutely produced 
an increase in mice exploratory activity of learning and reverted 
drug-induced amnesia (36). Furthermore, T1AM not only 
stimulated learning but also consolidated memory in the 24-h 
training session (33, 34) an effect consistent with pERK1/2, a 
master regulator of de novo synthesis of proteins necessary for 
memory consolidation. Interestingly, stimulation of learning was 
not observed in mice pretreated with clorgyline and with anti-
histaminergic treatments. This evidence confirmed the role of 
MAO-B catalysis in the generation of a pro-learning compound 
and indicated the involvement of the histaminergic system (5, 34).
Interestingly, recent in  vitro evidence obtained in isolated 
striatal slices gave indication on a receptor-mediated mechanism 
of T1AM. In particular, Zhang et al. (37) demonstrated T1AM, 
by activating TAAR1, promoted phosphorylation of thyroxine 
hydroxylase, thus prompting the synthesis of dopamine and its 
release. Interestingly enough, in the striatum, the main MAO 
isoform expressed is type B, which is the enzyme involved in 
T1AM (but also dopamine) degradation (20). Furthermore, 
other recent evidence also indicates that the release of dopamine 
in the striatum may be controlled by histamine released from 
the tuberomammillary nucleus, via H1 and H2 receptors (38). 
Overall, these results suggest T1AM might sustain dopamine 
synthesis and release acting at high-affinity targets (TAARs) and, 
indirectly, releasing histamine from the hypothalamic neurons. 
Both mechanisms might sustain an effectiveness of T1AM in 
basal ganglia diseases.
Furthermore, T1AM was also indicated as an activator of 
the serotoninergic type 1 subtype b receptor in virtue of heter-
odimerization of this receptor with TAAR1 (39), a finding that 
suggests possible antidepressant effectiveness of the amine.
However, the effects of T1AM on dopamine release and on 
the activation of the serotonin receptor need to be conclusively 
demonstrated in in vivo settings.
SiMiLARiTieS AnD DiFFeRenCeS in 
BeHAviORAL eFFeCTS inDUCeD BY 
PHARMACOLOGiCAL ADMiniSTRATiOn 
OF T1AM AnD TA1
If TA1 is T1AM active principle, then the pharmacological 
administration of TA1 should reproduce at least some of the 
effects described for T1AM. This assumption does not consider 
that TA1 pharmacologically administered might not have the 
same pharmacokinetic features of the acid produced in  situ by 
T1AM deamination. Among these differences, TA1 pharmacoki-
netic does not include the activity of MAO.
Musilli et al. (40) studied the effect of TA1 i.c.v. injected on 
memory, pain, and plasma glycemia. This study indicated TA1 
effect on memory was more composite than that of T1AM. In 
fact, at a low dose (0.4 µg/kg) the acid produced amnesia while 
at 1.32 and 4  µg/kg it stimulated learning without inducing 
memory consolidation. Interestingly, only the pro-learning effect 
was prevented by anti-histaminergic treatments. In particular, in 
the presence of zolantidine, TA1 turned out to be amnestic at 
all the doses tested. These differences in respect of T1AM effects 
on memory might relay on the pharmacokinetics of the acid but 
definitively prove that activation of the histaminergic system is 
triggered by TA1. However, TA1 present in the synaptic cleft may 
interact also with its own targets involved, for instance, in the 
amnestic effect. At the same pro-learning doses, TA1 induced 
hyperalgesia and hyperglycemia showing inverted U-shaped 
dose–effect curves (41) (Figure  2). Hyperalgesia and hyper-
glycemia were again modulated by anti-histaminergic drugs.
Hoefig et al. (42) reported that TA1 i.p. administered to mice at 
doses much higher (5 mg/kg) than those used by Manni et al. (15), 
did not induce hypophagia, hyperglycemia, and hypothermia 
thus confuting the hypothesis TA1 was the mediator of T1AM 
hypothalamic effects. Moreover, before concluding on this, it is 
noteworthy to recall that T1AM was not able to induce hyper-
glycemia when administered at high doses and the hypophagic 
effect of T1AM was found independent of MAO inhibition (15). 
Collectively, these data instead reinforced the hypothesis that 
T1AM and TA1, pharmacologically administered, have the pos-
sibility to activate their own target but that they share a common 
intracellular mechanism.
Laurino et al. (41) indicated that TA1, systemically adminis-
tered, deeply affected mouse sensitivity to noxious and painful 
stimuli. As for T1AM, the reduction of pain threshold resulted to 
be dependent on histamine release and associated with ERK1/2 
activation in DRG neurons.
3-Iodothryoacetic acid, as T1AM, systemically administered, 
increased mouse vigilance. In particular, TA1 stimulated the 
wakefulness of mice induced to sleep by a high ethanol dose (43), 
without interfering with the GABaergic transmission.
TA1 Mechanism of Action: Possible 
Hypotheses
How TA1 activates the histaminergic system remains to be 
elucidated. In this respect, it is unlikely that TA1 works as a 
histamine type 3 receptor antagonist since it lacks the neces-
sary chemical requisites to recognize the receptor. From our 
study, we can also exclude TA1 may interact at muscarinic and 
GABA-A receptors (43).
The study from Bellusci et  al. (34) indicated the chemical 
requisite for activating the histaminergic system. In particular, 
synthetic analogs of T1AM, lacking the iodide atom and the 
diphenoxyl moiety, were reported to stimulate, as T1AM, memory 
acquisition and retention depending on MAO activity and on H1 
receptor activation. Such results indicated that (i) the presence 
of the iodide and of the diphenoxyl moiety are not essential for 
activating the histaminergic system and (ii) the activation of the 
histaminergic system is secondary to intracellular accumulation 
of an acid compound that stimulates histamine release.
COnCLUSiOn
Pharmacological evidence indicates T1AM activates signaling 
pathways in different brain areas including the hypothalamus and 
the hippocampus, reproducing in rodents’ behavioral effects typi-
cally mediated by these brain areas. Such behaviors are dependent 
6Laurino et al. T1AM Metabolism in the Brain
Frontiers in Endocrinology | www.frontiersin.org June 2018 | Volume 9 | Article 290
on T1AM metabolism carried on by phase-I non-microsomal 
enzymes, producing TA1, and on the activation of the histamin-
ergic system-mediated accumulation of TA1.
Furthermore, T1AM may also interact with high-affinity 
targets on plasma membrane, including TAAR1. Of these two 
mechanisms, one may prevail over the other depending on T1AM 
doses or on the effect studied.
The study of T1AM pharmacological profile allowed to reveal 
a novel and yet unexplored link between T1AM, MAO (MAO-B), 
and the histaminergic system.
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